You are here
THERALOGICS, INC.
UEI: N/A
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease
Amount: $1,396,256.00DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, affect over one million Americans and significant unmet medical needs sti ...
STTRPhase II2012Department of Health and Human Services National Institutes of Health -
Evaluation of NBD Peptides as an Adjunct Therapy for the Treatment of Non-Hodgkin
Amount: $420,475.00DESCRIPTION (provided by applicant): The NF-?B family of transcription factors plays a central role in the regulation of lymphocyte proliferation, differentiation and survival. Aberrant constitutive a ...
STTRPhase I2010Department of Health and Human Services National Institutes of Health -
NF-kB Inhibition of Lung Ischemia Repurfusion Injury
Amount: $255,627.00DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) is a major problem in many clinical scenarios, including myocardial infarction and stroke. IRI is also a major problem in organ t ...
STTRPhase I2009Department of Health and Human Services National Institutes of Health -
Inhibition of IkK to treat lethal Graft-vs.-Host Disease
Amount: $885,556.00DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, th ...
STTRPhase II2008Department of Health and Human Services National Institutes of Health -
Blockade of NF-kappaB for Prevention/Treatment of GVHD
Amount: $244,488.00DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the ...
STTRPhase I2006Department of Health and Human Services National Institutes of Health -
Validation of a Novel NF-KB Inhibitor in Murine IBD
Amount: $216,950.00DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for th ...
STTRPhase I2006Department of Health and Human Services National Institutes of Health -
Validation of a Novel NF-KB Inhibitor in Murine IBD
Amount: $216,950.00DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for th ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Blockade of NF-kappaB for Prevention/Treatment of GVHD
Amount: $244,488.00DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health
